Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (NASDAQ: QTRX) reported that on July 15, 2026, it made an inducement equity grant to Jason Faessler in connection with his commencement as Chief Financial Officer and Treasurer. The award consists of 141,820 restricted stock units (RSUs), each representing one share of Quanterix common stock.
According to Quanterix, the RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the company or its subsidiaries. The grant was made under the Amended and Restated 2025 Inducement Plan as an inducement material to entering employment, in line with Nasdaq Listing Rule 5635(c)(4), and was approved by the Board’s Compensation Committee.
Quanterix (NASDAQ: QTRX) announced multiple milestones supporting broader clinical adoption of its LucentAD® Complete blood-based Alzheimer’s test. Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies cover qualifying blood-based biomarker testing, including LucentAD Complete, for eligible members meeting medical-necessity criteria, potentially impacting about 40 million members across 14 states.
According to Quanterix, a new peer‑reviewed study showed LucentAD Complete achieved high diagnostic parity versus an IP‑MS method and reduced diagnostic ambiguity about three-fold versus standalone plasma p‑Tau217. New AAIC 2026 data also support multi-analyte testing for earlier detection, with a 520-participant community study identifying preclinical Alzheimer’s in about 20% of cognitively normal adults.
Quanterix (NASDAQ: QTRX) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to three new employees effective June 15, 2026. The awards comprise 336,804 restricted stock units that vest in four equal annual installments, contingent on continued employment, under the Amended and Restated 2025 Inducement Plan.
Quanterix (Nasdaq: QTRX) appointed Jason Faessler as Chief Financial Officer, effective June 22. Faessler has extensive finance leadership experience in the life science tools industry, including senior roles at Bruker, PAREXEL, EMC (now Dell), and Harvard Business Publishing, supporting Quanterix’s strategic growth plans.
Quanterix (Nasdaq: QTRX) appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics, effective June 4, 2026.
He will lead Diagnostics strategy, initially focused on Alzheimer’s disease diagnostics, reporting to the CEO and joining the Executive Leadership Team.
Albrecht previously managed about $2.9 billion in revenue as Regional Vice President at Quest Diagnostics and brings extensive experience in commercial leadership, partnerships, operations, and governance.
Quanterix (Nasdaq: QTRX) announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, from June 8-10, 2026.
CEO Everett Cunningham will join a fireside chat on June 9 at 1:20 pm ET, with a live webcast and replay available on the company’s investor relations website.
Quanterix (NASDAQ: QTRX) granted an inducement equity award to new Chief Operating Officer Anthony Catalano on May 15, 2026. The award consists of 141,330 RSUs under the 2025 Inducement Plan, vesting in four equal annual installments, and was approved under Nasdaq Rule 5635(c)(4).
Quanterix (Nasdaq: QTRX) announced a planned transition of its Chief Financial Officer, Vandana Sriram. She will remain CFO through June 15, 2026 to support continuity while a search for her successor is underway.
According to Quanterix, the company is on solid financial footing, with a stated path to cash flow breakeven and synergy targets, supported by cost discipline and cash management.
Quanterix (NASDAQ: QTRX) reported Q1 2026 revenue of $36.4M (up 20% year‑over‑year) and ended the quarter with $102.6M in cash, cash equivalents, marketable securities, and restricted cash. GAAP gross margin was 42.7% and adjusted gross margin was 50.9%. Adjusted EBITDA loss narrowed to $9.8M. The company cites realized synergies from the Akoya acquisition, reiterated full‑year 2026 revenue guidance of $169–$174M, expects GAAP gross margin 41–45% and adjusted gross margin 49–53%, and anticipates cash‑flow breakeven in H2 2026 with year‑end cash near $100M and no debt.
Operationally, Quanterix announced collaborations with Tempus AI and Life Line Screening, PD‑BUILD participation, new assay and panel launches, and expects three clinical utility study completions plus an FDA 510(k) decision in H2 2026.
Lucent Diagnostics and Tempus AI (NASDAQ: TEM) announced a collaboration to integrate the LucentAD® Complete blood-based Alzheimer’s biomarker panel into Tempus Next care gap workflows and the Tempus clinical ordering platform.
The agreement makes LucentAD Complete available for neurologists to order via existing EHR integrations, aims to embed guideline-directed patient identification, and seeks to increase evaluation of patients eligible for approved Alzheimer’s treatments.